CAS NO: | 85118-33-8 |
包装 | 价格(元) |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Gaboxadol hydrochloride (Lu 02-030 hydrochloride) is a potent agonist of theGABAAreceptorand an antagonist ofGABACreceptors(IC50=25 μM). Gaboxadol hydrochloride displays a partial agonist efficacy on subunit α1β2γ2 with anED50value of 143 μM, a full agonist efficacy at α5 subunit (ED50=28-129 μM) and a superagonist efficacy at α4β3δ (ED50=6 μM). Gaboxadol hydrochloride is a non-opioid agent[1][2]. | ||||||||||||||||
IC50& Target | GABAAreceptor; GABACreceptor[1] | ||||||||||||||||
体外研究 (In Vitro) | Gaboxadol hydrochloride (0.34, 3.5 and 7.0 μM) decreses permeability across Caco-2 cell monolayers with a dose dependent manner, shows the mean Pappvalues with 8.1 × 10-6cm·s-1, 6.1 × 10-1cm·s-6and 5.6 × 10-6cm·s-1for 0.34, 3.5 and 7 μM gaboxadol, respectively[3]. | ||||||||||||||||
体内研究 (In Vivo) | Gaboxadol hydrochloride (intraperitoneal injection; 0.5, 1, 1.5, 2, 3, 4, or 5 mg/kg; once daily; three-day interval) normalizes the distance traveled by Fmr1 KO2 mice to WT activity levels at 0.5 mg/kg, additionally, this compound has no effect on locomotor activity in Fmr1 KO2 mice[2].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 176.60 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C6H9ClN2O2 | ||||||||||||||||
CAS 号 | 85118-33-8 | ||||||||||||||||
中文名称 | 加波沙朵; 盐酸加博沙多 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : ≥ 100 mg/mL(566.25 mM) DMSO : 75 mg/mL(424.69 mM;Need ultrasonic) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|